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Abstract
Background: HIV infection is characterized by ineffective anti-viral T-cell responses and impaired dendritic cell (DC)
functions, including response to Toll-Like Receptor (TLR) ligands. Because TLR responsiveness may affect a host’s response
to virus, we examined TLR ligand induced Myeloid and Plasmacytoid DC (MDC and PDC) activation of naı ¨ve T-cells in HIV+
subjects.
Methods: Freshly purified MDC and PDC obtained from HIV+ subjects and healthy controls were cultured in the presence
and absence of TLR ligands (poly I:C or R-848). We evaluated indices of maturation/activation (CD83, CD86, and HLA-DR
expression), cytokine secretion (IFN-alpha and IL-6), and ability to activate allogeneic naı ¨ve CD4 T-cells to secrete IFN-
gamma and IL-2.
Results: MDC from HIV+ subjects had increased spontaneous IL-6 production and increased CD83 and CD86 expression
when compared to MDC of controls. MDC IL-6 expression was associated with plasma HIV level. At the same time, poly I:C
induced HLA-DR up-regulation on MDC was reduced in HIV+ persons when compared to controls. The latter finding was
associated with impaired ability of MDC from HIV+ subjects to activate allogeneic naı ¨ve CD4 T-cells. PDC from HIV+ persons
had increased spontaneous and TLR ligand induced IL-6 expression, and increased HLA-DR expression at baseline. The latter
was associated with an intact ability of HIV PDC to activate allogeneic naı ¨ve CD4 T-cells.
Conclusion: These results have implications for the ability of the HIV+ host to form innate and adaptive responses to HIV
and other pathogens.
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Introduction
HIV+ individuals have reduced immune responses to viral
antigens and vaccines [1,2,3,4]. HIV disease progression is associated
with increased microbial translocation and systemic immune
activation [5]. TLR recognition of HIV or microbial products may
contribute to systemic immune activation and immune impairment
[6,7]. However, the effects of immune activation on TLR signaling
and ability of DC to activate naı ¨ve T-cells remain unclear.
Myeloid and Plasmacytoid DC subsets (MDC and PDC) can be
defined by expression of specific cell surface markers and TLRs.
MDC express BDCA-1 and CD11c, while PDC express BDCA-2,
BDCA-4, and CD123. TLR3 is selectively expressed in MDCs,
while PDC express TLR7 and 9 [8,9,10]. TLR mediated DC
activation provides a first line defense against invading pathogens
by inducing maturation, cytokine production, and costimulatory
molecule expression. Each of these contribute to the generation of
pathogen-specific T-cell activation [11,12].
Alterations in DC numbers, phenotype, and function exist in
HIV+ subjects [13,14,15,16,17,18]. However, factors underlying
these alterations remain poorly understood. Peripheral MDC and
PDC numbers are decreased during acute HIV infection [19].
Evidence indicates both cellular redistribution to lymph nodes and
cell death may contribute to lower peripheral blood DC numbers
[20,21,22]. DC TLR responsiveness in HIV infection has been
described as both intact [23,24] and reduced [25,26]. Conflicting
findings may result from differences in patient cohorts, cell culture
conditions, and TLR stimulus. Additionally, selective defects in
TLR signaling pathways or signaling tolerance may exist in a state
of chronic immune activation. For example, LPS tolerance is well
described in monocytes, where prior LPS exposure results in
impaired LPS induced TLR4 signaling [27]. In addition, during
HIV infection Tilton et al described a tolerance effect inhibiting
PDC IFN-a production [28]. Whether microbial translocation vs.
high HIV levels contribute to TLR signaling tolerance in DC is
not clear.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23884To investigate the relationship between immune activation and
DC phenotype and function, we specifically focused here on direct
ex vivo analysis of DC activation state, TLR ligand induced DC
activation, and TLR ligand dependent, DC dependent naı ¨ve CD4
T cell activation. Results show both MDC and PDC from HIV+
subjects are increased in activation phenotype directly ex vivo.
MDC PDL-1 as well as MDC secreted IL-6 were found to be
associated with HIV level. In addition, we found selective defects
in MDC and PDC responsiveness to TLR ligand, and MDC
ability to activate naive CD4 T-cells. These defects in MDC TLR
responsiveness appear related to systemic immune activation.
Methods
Study subject identification and IRB approval
HIV+ subjects (n=31) had detectable HIV antibodies by
ELISA and Western Blot, CD4 cell count $250, and had not
received HIV therapy for at least 3 months. They were
seronegative for Hepatitis C and hepatitis B surface antigen
negative. The median (range) of clinical indices were as follows:
age 41(23–54), plasma HIV 16534(400–490,000) C/ml, CD4
535(115–1139) 10
6/L, nadir CD4 412(115–999) 10
6/L, ALT
38(20–71) U/L, AST 22(10–55) U/L, total bilirubin 0.4(0.2–1.0)
mg/dL, platelets 225.5(105–485) K/cmm. Eight subjects were
known to have had previous therapy for HIV. 45% were female.
Healthy control subjects (n=28) were recruited in a similar age
range, 32(21–61), and similar sex distribution (46% female). All
study subjects provided written informed consent under the
approval of the institutional review board for human studies at
University Hospitals of Cleveland.
Cell isolation
PBMC were fractionated into PDC (positive BDCA-4 selection)
and MDC (CD19+ cell depletion followed by BDCA-1 selection)
(Miltenyi Biotec). Purity was .80% for MDC (CD11c+ HLA-
DR+) and .70% for PDC (BDCA-2+, HLA-DR+), and purity did
not differ between study groups.
Naive CD4 T-cells (97% CD3+CD4+CD45RA+cells) from a
single healthy leukapheresis donor were negatively selected
(Miltenyi Biotec), and frozen in aliquots to be utilized in assays
with freshly isolated DC.
DC phenotype and TLR-induced DC activation
MDC were stained with CD11c-APC, CD83-FITC, HLA-DR-
PERCP, and CD86-PE antibodies (BD Biosciences), and PDC
were stained with BDCA-2-APC (Miltenyi Biotec), CD83-FITC,
HLA-DR-PERCP, and CD86-PE antibodies, and analyzed by
flow cytometry (FACSCalibur; BD Biosciences) using CellQuest
software (BD Biosciences). Additional phenotypic analysis of MDC
was performed using PDL1-PE-CY7 (ebioscience), CD11c-Pacific
Blue, PDL2-PE, and ILT3-APC antibodies (BD Bioscience) on a
BD LSRII (BD Biosciences).
Isolated PDC and MDC were cultured (20 hr/37uC) in
complete RPMI 1640 medium (Invitrogen Life Technologies)
supplemented with 1% penicillin-streptomycin,1% L-glutamine,
and 5% human AB serum (Gemini Bio-Products) in the presence
or absence of TLR ligand. (MDC TLR3 ligand poly I:C 50 mg/
ml, Amersham Biosciences; PDC TLR7 ligand R-848 (resiqui-
mod, 1 mg/ml, InvivoGen). TLR ligands were chosen based on
previous experiments comparing DC stimulated with various
TLRs for optimal ability to activate allogeneic naı ¨ve CD4 T-cells
(not shown). Following culture, cells were analyzed by flow
cytometric analysis. Cell culture supernatants were analyzed for
IL-6 and IFN-a by ELISA (IL-6, eBioscience; IFNa, BioSource
International). In addition, IL-6 mRNA level was measured in
freshly isolated MDC following RNA isolation with DNase
treatment (Qiagen), and cDNA synthesis with RT-PCR analysis
(RT
2 Profiler PCR array SuperArray-ABI StepOnePlus).
Serum sCD14
Serum sCD14 was measured by ELISA method using a
commercial kit, as recommended by the manufactures instruction
(Biosource International).
DC activation of naive CD4 T-cells
Isolated MDC and PDC from each healthy control or HIV
infected donor were tested in increasing numbers (1,000, 3,000,
and 10,000 cells/well) for ability to activate allogeneic naive CD4
T-cells (2610
5/well) that were obtained from one healthy control
donor using an IFN- c ELISPOT assay to measure TLR ligand
dependent, DC dependent T cell activation. DC-T-cell co-cultures
were performed in the presence or absence of TLR ligand (ligand
present for entire culture). Cells were placed into 96-well round-
bottom plates (48 hr/37uC), then transferred to ELISPOT plates
pre-coated with IFN-c capture antibody for 20 hr at 37uC. Plates
were developed and analyzed as described previously for IFN-c
producing spot forming units [29,30]. We have previously utilized
this assay system that has characteristics of a very low background
signal in the absence of DC, and clear signal in the presence of
titrated DC numbers [31]. T cell activation is also very sensitive to
DC targeted TLR ligand (with no TLR mediated T cell activation
in the absence of DC), providing a suitable method for analysis of
DC function across a spectrum of allogeneic donors. T-cell IL-2,
IL-10, and IL-17 production was analyzed in 3 day supernatants
by ELISA (IL-2-ebioscience; IL-10, IL-17A or IL-17F-R&D
systems).
Cell viability was evaluated by removing cells following day 3 of
culture and staining with AnnexinV-FITC, and CD3-PERCP,
CD4-PE, and CD27-APC antibodies (BD Bioscience). Immediate
analysis was performed on the BD FACSCaliber.
Statistical analysis
We used conventional measures of central tendency and
dispersion to describe the data and compared continuous variables
by Mann-Whitney’s U test or Kruskal-Wallis’ test as needed. We
compared proportions by Fisher’s exact test. To assess associations
between continuous variables, we used Spearman’s rank correla-
tion coefficient, as well as partial correlations to control for the
effect of intervening variables when needed. All tests of
significance are two-sided, and a p value,0.05 was considered
to be significant.
Results
HIV+ subject DC exhibit increased maturation
To identify DC maturation state directly ex vivo we evaluated
freshly isolated MDC and PDC for maturation marker (CD83,
CD86, and HLA-DR) expression as shown in Fig. 1A. Comparing
DC maturation state between HIV+ subjects and healthy controls,
we observed higher CD86 and CD83 expression on HIV+ subject
MDC (HIV vs. Controls, 338 vs. 215 CD86 MFI; 50.3 vs. 37.5
CD83 MFI; p=0.003 and p=0.008 respectively; Fig. 1B). At the
same time HIV+ subject PDC exhibited greater HLA-DR
expression 614 vs. 469; p=0.04; Fig. 1B) and tended to express
more CD86 and CD83 (54 vs. 38 CD86 MFI; and 42 vs. 35 CD83
MFI 42; p=0.08 and p=0.06; Fig. 1B). These data are consistent
with enhanced DC activation during HIV infection, and are in
agreement with a previous report [20].
Altered MDC Activation State and Function in HIV
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e23884MDC from HIV+ subjects have less HLA-DR expression in
response to poly I:C stimulation in vitro
We next evaluated DC subset TLR ligand responsiveness by
measuring costimulatory marker (HLA-DR, CD86, and CD83)
upregulation and cytokine (IL-6 and IFN-a) secretion following
overnight culture in the absence or presence of TLR ligand. As
shown in Fig. 2A, CD86 expression was upregulated on MDC in
most subjects in response to poly I:C. However, the degree of
Figure 1. HIV subject DC exhibit increased maturation. Panel A. Representative flow cytometric analysis of freshly isolated MDC and PDC
from one healthy control. Mean Fluorescent Intensity (MFI) for HLA-DR, CD86, and CD83 were analyzed. Panel B. Baseline activation/maturation
phenotype of freshly isolated MDC and PDC from healthy control (n=22) and HIV+ subjects (n=24). The black line represents the median MFI value
for each group for HLA-DR, CD86, and CD83.
doi:10.1371/journal.pone.0023884.g001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e23884Figure 2. DC TLR ligand responsiveness. Panels A and B. CD86 MFI and HLA-DR MFI on isolated MDC following overnight culture in presence of
Medium and poly I:C stimulation in healthy control (n=21) and HIV+ subjects (n=18). The p value in panel B is for comparison between the delta
HLA-DR MFI for controls and HIV infected subjects . IL-6 production from isolated MDC on a subset of the same subjects (n=18 control and n=16
HIV+)( panel C) following overnight culture in absence and presence of poly I:C stimulation. IL-6 production from isolated PDC on a subset of the
same subjects (n=17 control and n=17 HIV+)( panel D) following overnight culture in absence and presence of R848 stimulation. Healthy control
(n=17) and HIV+ subject (n=16) PDC IFN-a production in response to overnight R848 stimulation is shown in panel E. Panel . Association between
MDC spontaneous IL-6 production and HIV plasma level.
doi:10.1371/journal.pone.0023884.g002
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the HIV+ group (204 vs. 626, p=0.1, Table 1), with CD86 MFI
on MDC of HIV+ subjects tending to be higher following culture
in medium and tending to be lower following poly I:C culture
(medium controls 504 vs. HIV 626, p=0.2; and poly I:C controls
1031 vs. HIV 856, p=0.5; Fig. 2A). Similar results were observed
for HLA-DR expression on MDC, with reduced TLR ligand
induced upregulation of HLA-DR on MDC of HIV+ subjects
(delta HLA-DR MFI controls 193 vs. HIV 220, p=0.02, Fig. 2B
and Table 1). In contrast, no differences were observed in MDC
CD83 expression or upregulation between groups. PDC expres-
sion of all markers were comparable between groups in the
absence and presence of R848 (not shown), except R848 induced
CD86 upregulation tended to be lower in HIV+ subjects (delta
CD86 MFI controls 411 vs. HIV 272, p=0.1, Table 1). These
results suggest DC, particularly MDC, from HIV+ subjects have
reduced responsiveness to TLR stimulation, as reflected by
reduced upregulation of HLA-DR.
To further investigate DC maturation and activation state we
evaluated cytokine production. MDC and PDC from HIV+
subjects had increased spontaneous IL-6 production (Fig. 2C and
2D). This result was further validated using RT-PCR measuring
IL-6 mRNA levels in freshly isolated, uncultured MDC from a
subset of individuals (n=4/group). We found a 3 fold increase in
IL-6 mRNA levels in MDC from HIV+ subjects compared to
controls (p=0.004, not shown). Following TLR stimulation,
MDC IL-6 production was comparable between groups, while
PDC IL-6 was increased in HIV+ subjects (MDC control 512 pg/
ml vs. HIV 676 pg/ml p=0.4, Fig. 2C; and PDC control 495 pg/
ml vs. HIV 1020 pg/ml, p=0.03, Fig. 2D). We observed no
difference in the degree of IL-6 upregulation following TLR ligand
stimulation between groups (MDC controls 414 pg/ml vs. HIV
324 pg/ml, p=0.22; and PDC controls 282 pg/ml vs. HIV
333 pg/ml, p=0.8, Table 1). However, we found R848 induced
PDC IFN-a production tended to be lower HIV+ subjects (control
1514 pg/ml vs. HIV 581 pg/ml p=0.1, Fig. 2E). Greater
spontaneous IL-6 production from the DCs is consistent with
prior in vivo activation. Additionally, the intact R848 induced
PDC IL-6, yet somewhat reduced IFN-a production, is consistent
with selective TLR7 signaling pathway alteration.
Analysis of relationships between immune parameters and
clinical indices (HIV level, CD4 T-cell count, sex, age, prior HIV
therapy status) indicate a positive correlation between MDC
spontaneous IL-6 production and plasma HIV level (r=0.5,
p=0.02; Fig. 2E) consistent with virus level affecting MDC
activation state.
MDC from HIV+ subjects are impaired in activating
allogeneic naı ¨ve CD4 T-cells, while PDC activating
capacity is intact
Prior studies evaluating DC ability to prime T-cell responses in
HIV+ subjects have utilized allogeneic PBMC as responder cells
and have not focused on the effects of TLR ligands on the ability
to enhance activity [18,32]. Here we specifically focused on TLR
ligand dependent DC ability to activate allogeneic naı ¨ve CD4 T-
cells to produce IFN-c and IL-2 in the absence and presence of
TLR ligand stimulation. MDC from both control and HIV+
subjects induced naı ¨ve CD4 T-cell IFN-c production (Fig. 3A).
However, HIV+ subject MDC induced significantly fewer IFN-c
producing cells compared to controls (p=0.03; Fig. 3A). In the
presence of poly I:C stimulation, we observed a similar defect in
HIV+ subject MDC induction of IFN-c producing cells (p=0.04;
Fig. 3B). Similar results were observed for IL-2 production, though
this did not reach statistical significance. HIV+ subject MDC
tended to induce less CD4 T-cell IL-2 compared to controls both
in the absence and presence of poly I:C stimulation (0 vs. 16.6 pg/
ml, p=0.4, Fig. 3C; and 5.4 vs. 197.7 pg/ml, p=0.3; Fig. 3D). In
contrast, the ability of PDC to induce CD4 T-cell IFN-c and IL-2
was comparable between groups both in the absence and presence
of R848 stimulation (Fig. 4). These results indicate a selective
defect in the ability of MDC to activate naı ¨ve CD4 T-cells in
HIV+ subjects.
PDL1 and PDL 2 expression are increased on MDC from
HIV+ subjects and are associated with HIV level
To further investigate the defect in naı ¨ve CD4 T-cell activation
by HIV+ subject MDC, we measured expression of inhibitory
molecules. PD1 is known to inhibit naive T-cell activation [33]
and PD1 expression is increased on HIV specific T-cells [34]. The
ligand for PD1, PD-L1, has been shown to be expressed at
increased levels on MDC, CD14+, and CD19+ cells from HIV+
subjects, and expression is related to markers of HIV disease stage
[32,35] At the same time, TLR ligands derived from HIV directly
upregulate PD-L1 on DC and monocytes in vitro [36]. We
therefore investigated expression of PD-L1, along with other
inhibitory receptors PDL-2 and ILT3 [37,38,39]. As shown in
Figures 5A and 5B, PD-L1 and PDL-2 expression tended to be
increased on MDC from HIV+ subjects (p=0.1 and p=0.07,
respectively), while no difference in ILT3 expression was observed
between groups (not shown). Furthermore, expression of PD-L1
on MDC was positively correlated with plasma level of HIV RNA
(r=0.9, p=0.002, Fig. 5C) and negatively correlated with CD4 T-
cell count (r=20.76, p=0.03, not shown).
To determine whether the increased PDL-1 or PDL-2
expression on MDC from HIV+ subjects contributed to T-
cell apoptosis [40], we measured AnnexinV staining on T-cells
following 3 day naive T-cell-MDC cocultures. We did not
o b s e r v ea n yd i f f e r e n c ei np e r c e n t a g eo fA n n e x i n V + T-cells
comparing naive T-cells cocultured with MDC from HIV+
subjects vs. controls in either the absence or presence of TLR
ligand (p=0.7 and p=0.3; Fig. 5D). We also evaluated whether
MDC from HIV+ subjects were more likely to induce T-cell
IL-10 or IL-17 secretion. We observed limited induction of IL-
10 in both the absence and presence of TLR stimulation in
control (3.5 pg/ml and 5.3 pg/ml) and HIV+ subject (2 pg/ml
and 2.6 pg/ml) MDC-T-cell cocultures with no statistical
difference between groups (not shown). IL-17 levels were
undetectable by ELISA method (not shown). We therefore
found no evidence of CD4 cytokine variation in response to
HIV+ subject MDC.
Table 1. Change in maturation marker expression following












MDC Controls 193 626 11 414 NT
HIV+ 220 204 7 324 NT
p value p=0.02 p=0.1 p=0.25 P=0.22 NT
PDC Controls 407 411 1 282 1515
HIV+ 217 272 2 333 581
p value p=0.5 p=0.11 p=0.7 P=0.8 p=0.1
doi:10.1371/journal.pone.0023884.t001
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HIV+ subjects following TLR ligand stimulation are
associated with reduced naı ¨ve CD4 T-cell activation
To investigate the mechanism underlying the failure of MDC
from HIV+ subjects to activate naı ¨ve CD4 T-cells, we evaluated
associations between MDC activation state and naı ¨ve CD4 T-cell
response. Within the HIV+ group, MDC responsiveness to TLR
ligand, as measured by HLA-DR, CD86, and IL-6 upregulation,
was correlated with ability to activate naı ¨ve CD4 T-cells (r=0.47,
p=0.08; r=0.6, p=0.03; and r=0.55, p=0.03, respectively). In
control subjects, baseline HLA-DR expression and upregulation of
CD86 and IL-6 in response to TLR ligand were correlated with
MDC ability to active naive CD4 T-cells (r=0.6, p=0.02; r=0.6,
p=0.01; and r=0.7, p=0.01). These data are consistent with
HLA-DR and CD86 playing an important role in naı ¨ve T-cell
activation in both control and HIV+ subject sample cultures, and
are consistent with our earlier data indicating a strong costimu-
latory dependence in this naı ¨ve CD4 T-cell activation assay system
[31]. These data suggest that the reduced upregulation of
costimulatory molecules in MDC of HIV+ subjects following
TLR ligand stimulation may contribute to the observed defect in
ability to activate naı ¨ve CD4 T-cells.
Biomarkers of systemic immune activation and microbial
translocation have been associated with increased activation state
of CD8 T-cells and monocytes in HIV+ individuals [5], so we
investigated the relation between immune activation and DC
phenotypeand function.WemeasuredsCD14,amarkerofsystemic
immune activation that is shed from monocytes upon LPS binding
and activation [41]. Consistent with prior literature [5],[42], we
observedgreatersCD14intheserumofHIV+ subjectscomparedto
controls (2.35 mg/ml vs. 1.6 mg/ml p=0.03; not shown). Interest-
ingly, we found a negative correlation between sCD14 level and
MDC HLA-DR expression observed after TLR ligand stimulation
(r=20.9, p=0.04; not shown) in HIV+ subjects, while no such
relationship was observed in healthy control samples.
Discussion
We evaluated DC subset phenotype and function in relation to
systemic immune activation during HIV disease. Results indicate
both MDC and PDC from HIV+ subjects have increased
expression of maturation markers when analyzed directly ex vivo.
In addition, we observed MDC from HIV+ subjects to be
refractory in response to TLR stimulation, with reduced
upregulation of HLA-DR expression in response to poly I:C.
PDC from HIV+ subjects tended to have reduced upregulation of
both CD86 expression and IFN-a production following TLR7
stimulation. Further investigation revealed MDC dependent naive
CD4 T-cell activation was impaired in HIV+ subjects, while PDC
dependent naive CD4 T-cell activation was intact. Results indicate
multiple factors that may contribute to the MDC defect, including
Figure 3. HIV subject MDC are impaired in naı ¨ve CD4 T cell activation activity. Freshly prepared MDC from healthy control (n=17) and
HIV+ (n=18) subjects were used in titrated numbers (x-axis) to activate one healthy control subject’s allogeneic naive CD4 T-cells to produce IFN-c or
IL-2 (y-axis) in a 72-h culture performed in the absence (Medium, panels A. and C.), or presence of poly I:C (panels B. and D.). Control cultures of
TLR ligand and naı ¨ve CD4 T cells resulted in ,3 sfu IFN-c, and data shown are sfu above this background.
doi:10.1371/journal.pone.0023884.g003
Altered MDC Activation State and Function in HIV
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which is associated with HIV plasma level, and defective
responsiveness to TLR ligand stimulation which is associated with
systemic immune activation (serum sCD14). Circulating immature
DC are thought to exist in a quiescent state, expressing low levels
of costimulatory molecules and cytokines [43]. Upon recognition
of microbial pathogens, DC mature, express costimulatory
molecules, and secrete cytokines to facilitate T-cell activation
[44,45]. Our results indicate circulating MDC and PDC from
HIV+ subjects express increased levels of costimulatory molecules
and IL-6 directly ex vivo, suggesting DC maturation is perturbed
during HIV disease. These phenotypic data are supported by a
previous report by Dillon et al., in which both DC subsets were
found to have altered chemokine receptor and maturation marker
expression [20]. A new finding here is the observation of a positive
correlation between spontaneous MDC IL-6 expression and
plasma HIV levels, consistent with the relationship between DC
CD40 expression and HIV RNA noted by Dillon et al. These
results suggest HIV may directly perturb DC maturation
phenotype in vivo, possibly through DC interactions with HIV
proteins and/or viral RNA, both shown to induce DC maturation
in vitro [6,46]. Additionally, monocyte activation through direct
contact with translocated microbial products may indirectly affect
DC activation/maturation state, and our observed association
between serum sCD14 and DC HLA-DR expression in response
to TLR ligand could be consistent with the latter.
The ability of immature DC to mature, via TLR activation, is a
critical step in generating an effective immune response. In our
HIV+ subject samples, we observed selective defects in MDC and
PDC responsiveness to TLR stimulation. One previous study
evaluating TLR responsiveness in HIV+ subjects reported TLR7
stimulated PBMC have decreased PDC CD83 expression and
IFN-a production [25,28], while another study reported increased
TNF-a production [23]. Discrepancies in TLR responsiveness are
likely due to differences in the TLR ligand used and response
parameters measured. In fact, our data support this notion in that
alterations in DC TLR signaling pathways are selective and
discrete. Specifically, ability of PDC to secrete IFN-a and
upregulate CD86 in response to TLR7 stimulation appears
impaired, while IL-6 production is intact. At the same time,
MDC have reduced HLA-DR upregulation in response to TLR3
stimulation, despite having intact IL-6 production. One possible
mechanism by which MDC and PDC become partially attenuated
in response to TLR stimulation is through prior activation in vivo
with resulting refractory responsiveness, as previously discussed in
the context of PDC IFN-a production [28]. This concept is
supported here by the baseline increase in DC activation state.
Alterations in DC dependant activation of T-cells have been
described in the setting of chronic HIV infection, using purified
DC subsets [18,47]. Specifically, MDC and PDC from HIV+
subjects were found to be impaired in stimulating unfractionated
PBMC T-cell proliferation and cytokine production. The
Figure 4. HIV subject PDC are intact for naı ¨ve CD4 T cell activation activity. Freshly prepared PDC from healthy control (n=13) and HIV+
(n=10) subjects were used in titrated numbers (x-axis) to activate one healthy control subject’s allogeneic naive CD4 T-cells to produce IFN-c or IL-2
(y-axis) in a 72-h culture performed in the absence (Medium, panels A. and C.), or presence of R848 (panels B. and D.). Control cultures of TLR
ligand and naı ¨ve CD4 T cells resulted in ,3 sfu IFN-c, and data shown are sfu above this background.
doi:10.1371/journal.pone.0023884.g004
Altered MDC Activation State and Function in HIV
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[18], and these assays likely reflect a combination of memory and
naive T cell activation. Since TLR responsiveness may be
particularly important for DC activation and ability of DC to
activate naı ¨ve T-cells, we focused here specifically on this
interaction. We also focused on naı ¨ve T cell activation, eliminating
any contribution of memory T cell activation. We found MDC
from HIV+ subjects, despite having increased cytokine and
costimulatory molecule expression at baseline, are less able to
activate naı ¨ve CD4 T-cells both in the absence and presence of
TLR3 stimulation. Observed correlations between ability to
upregulate costimulatory molecules CD86 and HLA-DR in
response to TLR stimulation, and ability to activate naı ¨ve CD4
T-cells, suggest a common mechanism underlies decreased
responsiveness to TLR stimulation and defective MDC dependant
naı ¨ve T-cell activation. Additionally, increased PDL1 and PDL2
expression on HIV+ subject MDC may contribute to impaired
naı ¨ve CD4 T-cell activation as has been previously suggested [48].
Our data are in support of this possibility, and this is supported
further by previous data showing enhanced MDC dependant
memory T-cell activation in the presence of PDL1-PD1 blockade
[32]. Notably, we did not find an alteration in T cell annexin
staining in the present assays, suggesting the PDL1/2 effect does
not likely result in T cell death during the time frame of the assay
performed here. In contrast to MDC, PDC were found here to
have intact naı ¨ve T-cell activation activity, and this was positively
correlated with TLR7 induced HLA-DR expression and IL-6
production, which were also intact in HIV+ subjects. These results
indicate a distinct functional defect in MDC naive T-cell
activation, emphasizing selective alterations exist in MDC and
PDC during HIV infection.
Engagement of different signaling pathways in separate DC
subsets may contribute to the selective defects observed. One
possibility is that differential activation of DC subsets occurs
through different pathogen recognition receptors by either HIV,
or other microbial products present during HIV infection. These
stimuli could engage distinct signaling cascades within each DC
subset, rendering each cell type with selective defects in
responsiveness to subsequent TLR stimulation. Indeed, HIV
ssRNA has been shown to directly induce MYD88 dependent DC
maturation [6]. Here we observe a direct correlation between HIV
level and MDC PDL1/2 expression and IL-6 secretion, suggesting
HIV may play a direct role in activating DC in vivo. Of course,
indirect effects remain a possibility as well. Additionally, we also
observed a correlation between reduced MDC upregulation of
HLA-DR expression following TLR stimulation and increased
serum sCD14. sCD14 is thought to be released from cells activated
by LPS [41], suggesting that systemic exposure to translocated
microbial products in HIV infection [5] may also contribute to the
observed DC defect. Though the consequences of altered DC
maturation state are not fully understood, increased cytokine
production and refractory responsiveness are likely detrimental to
development of an effective immune response. For instance,
increased serum IL-6 level has been predictive for risk of
cardiovascular disease in the general population, and mortality
in HIV+ persons [49,50]. Therefore, excess IL-6 production by
Figure 5. Increased PDL-1 and PDL-2 expression on HIV subject MDC. Isolated MDC were evaluated for expression of inhibitory molecules
PDL-1 (panel A) and PDL-2 (panel B) in control (n=10) and HIV+ (n=10) subjects. Black lines represent median MFI value for each group. Panel C.
Association between PDL-1 MFI on MDC in HIV+ subjects and plasma HIV level. Panel D. The percentage of Annexin V+ T-cells are shown following
naive T-cell co-cultures with control vs. HIV+ subject MDC (10,000cells/well) in the absence and presence of poly I:C.
doi:10.1371/journal.pone.0023884.g005
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aimed at distinguishing the direct effects of HIV verses those of
other microbial elements indirectly resulting from HIV infection
on immune cell functions are required to guide more effective
vaccine strategies and immuno-modulatory therapies in the setting
of HIV infection.
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